Design and Synthesis of New PotentC₂-Symmetric HIV-1 Protease Inhibitors. Use ofl-Mannaric Acid as a Peptidomimetic Scaffold

Citations Over TimeTop 25% of 1998 papers

Abstract

A study on the use of derivatized carbohydrates as C2-symmetric HIV-1 protease inhibitors has been undertaken. L-Mannaric acid (6) was bis-O-benzylated at C-2 and C-5 and subsequently coupled with amino acids and amines to give C2-symmetric products based on C-terminal duplication. Potent HIV protease inhibitors, 28 Ki = 0.4 nM and 43 Ki = 0.2 nM, have been discovered, and two synthetic methodologies have been developed, one whereby these inhibitors can be prepared in just three chemical steps from commercially available materials. A remarkable increase in potency going from IC50 = 5000 nM (23) to IC50 = 15 nM (28) was observed upon exchanging -COOMe for -CONHMe in the inhibitor, resulting in the net addition of one hydrogen bond interaction between each of the two -NH- groups and the HIV protease backbone (Gly 48/148). The X-ray crystal structures of 43 and of 48 have been determined (Figures 5 and 6), revealing the binding mode of these inhibitors which will aid further design.

Related Papers

• → Design and Synthesis of New PotentC₂-Symmetric HIV-1 Protease Inhibitors. Use ofl-Mannaric Acid as a Peptidomimetic Scaffold(1998)77 cited
• → HIV-1 Protease Inhibitors: A Comparative QSAR Analysis(2003)39 cited
• → Structure Based Design of Inhibitors of Aspartic Protease of HIV-1(2005)9 cited
• → X-Ray Diffraction data from HIV-1 protease with a peptidomimetic inhibitor ("WT-SE"), source of 1FQX structure(2019)
• → Developments in peptide synthesis and peptidomimetic chemistry: HIV protease analogs and substrate-based inhibitors(2006)